I n a subset of individuals that are relatively young and otherwise healthy, life threatening ventricular arrhythmia can develop as a result of mutations in genes encoding ion channels, transporters, and accessory subunits that lead to altered cardiac electrophysiology. 1, 2 During the past 2 decades, significant progress has been made in the identification of genetic defects underlying many recognized types of inherited arrhythmia syndromes (IAS). However, for most of these inherited disorders, clinical management is still hindered by insufficient knowledge of the functional consequences of the candidate mutation. This is largely because of lack of suitable model systems that appropriately mimic human cardiac electrophysiology. For example, widely used transgenic mice have a heart rate of ≈8× faster than that of humans (500 versus 60 beats/ min), and the action potential duration (APD) in mouse cardiomyocytes is relatively shorter secondary to differences in K + currents. 3 In addition, variable disease expressivity and sensitivity to therapeutic interventions between mutations and patients necessitate more personalized treatment. The recent emergence of induced pluripotent stem cell (iPSC) technology 4,5 has provided an unprecedented opportunity for generating and studying iPSC-derived cardiomyocytes from diseased patients. iPSC-based studies allow investigation of patient-and mutation-specific disease mechanisms, as well as identification and assessment of novel and custom-tailored therapeutic strategies for arrhythmia syndromes.
I n a subset of individuals that are relatively young and otherwise healthy, life threatening ventricular arrhythmia can develop as a result of mutations in genes encoding ion channels, transporters, and accessory subunits that lead to altered cardiac electrophysiology. 1, 2 During the past 2 decades, significant progress has been made in the identification of genetic defects underlying many recognized types of inherited arrhythmia syndromes (IAS). However, for most of these inherited disorders, clinical management is still hindered by insufficient knowledge of the functional consequences of the candidate mutation. This is largely because of lack of suitable model systems that appropriately mimic human cardiac electrophysiology. For example, widely used transgenic mice have a heart rate of ≈8× faster than that of humans (500 versus 60 beats/ min), and the action potential duration (APD) in mouse cardiomyocytes is relatively shorter secondary to differences in K + currents. 3 In addition, variable disease expressivity and sensitivity to therapeutic interventions between mutations and patients necessitate more personalized treatment. The recent emergence of induced pluripotent stem cell (iPSC) technology 4, 5 has provided an unprecedented opportunity for generating and studying iPSC-derived cardiomyocytes from diseased patients. iPSC-based studies allow investigation of patient-and mutation-specific disease mechanisms, as well as identification and assessment of novel and custom-tailored therapeutic strategies for arrhythmia syndromes.
This review provides a basic understanding of the fundamental electrophysiology of cardiac myocytes and the underlying mechanisms of IAS to help physicians and research scientists without expertise in this field to contribute toward the design of effective treatment strategies. The review will highlight the recent advances and opportunities from human iPSC-derived cardiomyocytes (hiPSC-CMs) models for investigating IAS and testing antiarrhythmic strategies.
Basis of Cardiomyocyte Excitability: Origin of the Membrane Potential
The heart is an electromechanical organ that pumps blood throughout the body undergoing ≈3 billion cycles in an average lifetime. 6 To perform this function in the most efficient way, the heart contracts and relaxes in a highly coordinated way (both spatially and temporally) during each heartbeat referred to as a cardiac cycle. Each cardiac cycle starts with an electrical impulse, originating from a group of specialized pacemaker cells called the sinoatrial node (SAN), which subsequently propagates throughout the heart. This electrical excitation of the heart is made possible by an electrochemical gradient that exists across the membrane of each heart muscle cell or cardiomyocyte. 6 The lipid bilayer membrane of a cardiomyocyte is embedded with integral proteins called ion channels that facilitate the passive diffusion of ions across the hydrophobic cell membrane. Ion channels are generally characterized by 2 important properties: (1) gating: ion channels open and close in response to a specific stimulus either binding of a ligand (eg, neurotransmitters) or changes in the transmembrane potential; (2) selectivity: ion channels allow a high rate of selective passage of only a particular species of ions, such as K + , Na + , Cl − , or Ca 2+ . The flux rate of channels is high, equivalent to 10 7 ions for a single monovalent channel current magnitude of 1 pA. These properties of ion channels coupled with the presence of large negatively charged molecules (mainly proteins) inside the cell and energy-requiring activity of membrane pumps (primarily the Na Figure 1A ) generating an electrochemical gradient which sets the membrane potential (MP). 7 When ion channels open, they bias the MP of the cell toward the equilibrium potential of the permeant ion. The equilibrium potential for each ion, which can be calculated by the Nernst equation, is the MP where the chemical and the electrical forces are in balance such that there is no net flow of ions through the open channel. For example, under resting conditions, an atrial or ventricular myocyte is permeable to K + because a specific type of K + channel (Kir2.1) is constitutively in an open state, whereas other types of ion channels are closed unless activated by a change in MP. For this reason, the resting MP (RMP) of a resting (ie, between beats) cardiomyocyte is steered toward the K + equilibrium potential of −90 mV. By convention, MP is measured as the voltage of the intracellular side of the membrane with respect to a ground electrode located outside the cell. 7 The direction of ion currents conducted by an ion channel (into the cell [inward] or out of the cell [outward] ) is determined by the electrochemical gradient of the permeant ions. For example, outward flow of K + ions through K + channels drive the myocyte toward −90 mV while inward flow of Na + ions through opening of voltage-gated Na + channels forces the MP toward a positive value (up to +40 mV).
Action Potential of a Human Cardiac Myocyte
An action potential (AP) is generated by the orchestrated opening and closing of multiple ion channels present in the plasma membrane of an individual cardiomyocyte that conduct depolarizing, inward (Na + and Ca
2+
) and repolarizing, outward (K + ) currents. 8 The AP waveform in different regions of the heart is distinct owing to differences in the expression and the properties of the underlying ion channels. These differences and the unique architecture of the cardiac conduction system (atrioventricular node and His-Purkinje system) contribute to the normal unidirectional propagation of excitation through the atria to the ventricles and to the generation of normal cardiac rhythms in the heart. 9, 10 Figure 1B illustrates the 5 phases (0-4) of a ventricular AP. Phase 4 represents the resting state in a normal working cardiomyocyte wherein the RMP is ≈−90 mV. During phase 0, a depolarizing stimulus from a neighboring cell elevates the RMP to the threshold at which voltage-gated Na + (Na V ) channels open, allowing Na + ions to rapidly diffuse into the cell down their electrochemical gradient. The rapid phase 0 depolarization shifts the MP toward the Na + equilibrium potential of +40 mV and is responsible for the rapid propagation of the cardiac impulse. Within a few ms after activation, Na + channels rapidly inactivate and thus are unable to conduct Na + . The depolarized MP results in a brief activation of the transient outward potassium current (I to ), that in turn leads to a brief, and only partial repolarization (phase 1). Phase 2 is the characteristic prolonged plateau phase of the cardiomyocyte AP, where inward and outward currents are nearly equal (hence only a minor change in MP 
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The inward and outward conductances during the plateau phase are delicately balanced, and modest changes during this phase can lead to differing AP morphologies, such as a spike-and-dome shape in the ventricular and a triangular shape in the atrial cardiomyocytes. Atrial AP also displays a less negative RMP, attributable to the reduced expression of Kir2.1. I to is more prominent in human atrial than in ventricular myocytes.
14 Moreover, atrial cells selectively express 2 additional K + currents; the ultrarapidly activating delayed outward rectifying current (I Kur ) and the acetylcholine-activated K + current (I KACh ) that are absent in ventricular myocytes. I KACh is small under normal conditions but it becomes prominent during increased vagal tone. 15 Activation of I Kur and I KACh during phase 3 explains the lower plateau potential and shorter APD of atria.
The AP morphology of pacemaker cells in the SAN and the atrioventricular node is significantly different from that of ventricular and atrial cells. A hallmark feature of pacemaker cells is their automaticity, that is, spontaneous beating in the absence of an external stimulus. The automaticity is driven by both voltage and Ca
2+
-dependent mechanisms and involves the funny current (I f ) carried by the hyperpolarization-activated cyclic nucleotide-gated channels. 16 In pacemaker cells, the RMP at the onset of phase 4 is more depolarized (−50 to −65 mV) compared with ventricular cells. Because of this depolarized RMP, the Na + channels are mostly inactivated. As a result, the phase 0 in pacemaker cells is mediated by the relatively slowly activating I CaL , leading to low upstroke velocity. Phase 1 is absent in pacemaker cells because of an absence of I to . Phase 2 repolarization again represents the balance between I CaL , I Kr , and I Ks , and the final phase 3 repolarization results from inactivation of I CaL and the recovery from inactivation of I Kr . I f activates at the end of phase 3 repolarization and contributes to the initiation of phase 4 diastolic depolarization. 
Excitation-Contraction Coupling
The synchronous beating of the heart depends on the coupling between the electrical activity (excitation) and the mechanical pumping (contraction), hence the name excitation-contraction coupling ( Figure 1C) . 18, 19 Excitation-contraction coupling involves finely controlled changes in the concentration of Ca 2+ ions inside the myocyte, raising the cytoplasmic [Ca 2+ ] from ≈60 to 100 nmol/L to 600 to 1000 nmol/L and activation of the contractile apparatus. 20 
Characteristics of hiPSC-CMs
Native human cardiomyocytes are ideal to study the molecular mechanisms associated with cardiac ion channel abnormalities. However, it is not only highly invasive and cumbersome to obtain cardiac tissue from patients but also not currently possible to maintain these cells in long-term culture. Consequently, the majority of functional studies on specific mutations associated with IAS have relied on overexpressing the mutated channels in heterologous expression systems, including Xenopus oocytes, human embryonic kidney cells, and Chinese hamster ovary cells. An important shortcoming of these models is that they lack crucial constituents of cardiac ion channel macromolecular complexes that might be required to reproduce the exact molecular and electrophysiological phenotypes linked with the mutation. 24 Transgenic mouse models have been useful in this regard (Table 1) , but substantial differences in gene expression profile and physiology between species severely limit the validity of extrapolating data from rodents to humans. For example, the heart rate in mice is ≈8× faster than that of humans and cardiac repolarization in mouse cardiomyocytes relies primarily on I to , I K,slow1 , I K,slow2 , and I SS ion currents, whereas in humans, repolarization is mostly dependent on I Ks and I Kr . In addition, Ca 2+ handling and myofilament proteins differ in expression and pathophysiology in mouse versus human hearts. 3 The recent discovery of somatic cell reprogramming to generate iPSCs 4, 5 has created great excitement because of the ability to produce for the first time, patient-and diseasespecific hiPSC-CMs. To generate hiPSCs, somatic cells can be obtained from patient's hair, blood, skin, fat, urine, or oral mucosa. 24, 49 These cells are then reprogrammed to a pluripotent state by introducing pluripotency-associated genes. The resulting iPSCs are then differentiated into cardiomyocytes by using several strategies (for review, see refs 50, 51 ). After ≈8 to 12 days, clusters of beating cells typically appear which on further maturation in culture can be enzymatically dissociated into single cardiomyocytes for molecular and functional analyses.
The patch clamp technique is the gold standard to measure various AP parameters from hiPSC-CMs that correspond to specific ionic current properties. These parameters include RMP or maximal diastolic potential (MDP), cycle length, AP amplitude, maximum upstroke velocity (d v /dt max ), and APD at various percentage levels of repolarization (ie, APD20, APD50, and APD90). For example, MDP/RMP reflects activity of steady state K + currents, primarily I K1 . The upstroke velocity reflects the magnitude of I Na while the AP durations (APDs) denote different phases of repolarization. APD20 is importantly regulated by I CaL and I to1 while APD90 is most dependent on I Ks and I Kr . 49 The common hiPSC differentiation protocols predominantly generate ventricular-like hiPSC-CMs 52,53 although protocols aimed at specifically generating atrial-like 36 and nodal-like 31 hiPSC-CMs have also been recently described. The distinction between different hiPSC-CMs is often made based on the AP morphology. For example, ventricular-like cells are characterized by a more negative MDP, a rapid AP upstroke, and a long plateau phase (see Figure 1B) . The absence of a prominent plateau phase is defined as a characteristic of atrial-like cells, resulting in shorter APD compared with ventricular-like APs. Nodal-like APs display more depolarized MDP, a slower AP upstroke, and a prominent phase 4 depolarization. 24 Recordings of subtype specific currents may also be used to distinguish atrial and nodal CMs within the hiPSC-CM population. For example, I Kur and I KACh are specific to atrial cells 36 while I f and T-type Ca 2+ current (I CaT ) are specific for nodal cells 31 (Table 1 ). In general, hiPSC-CMs are electrophysiologically immature compared with isolated adult ventricular CMs as reflected by the lower upstroke velocity (secondary to less negative MDP) and less prominent notch (phase 1). 24, 45 One of the most remarkable differences between hiPSC-CMs and native adult human primary CMs relates to the fact that hiPSC-CMs (including ventricular-like and atrial-like cells) display innate automaticity resulting in spontaneous beating, like in fetal human CMs. 24 This is because of substantially reduced density of I K1 and expression of pacemaker current (I f ) in hiPSC-CMs that is virtually absent in adult ventricular CMs. Recent studies have aimed to overcome these limitations by artificially enhancing the I K1 density through either viral overexpression of Kir2.1 54, 55 or by in silico injection of I K1 with kinetics of Kir2.1. 56, 57 Overexpression of Kir2.1 in human embryonic stem cell-derived cardiomyocytes abolished cell automaticity resulting in similar AP characteristics to those of adult CMs, but the Ca 2+ handling properties remained immature. 54 However, in a more recent study, enhanced Kir2.1 expression in hiPSC-CMs improved both AP and Ca 2+ handling properties. 55 Similarly, enhanced I K1 by in silico injection in hiPSC-CMs induced a more physiological Delayed outward rectifier K + channels: so named because of delayed onset in their activation, which starts during the plateau phase of AP. These are voltagegated K + (Kv) channels. They play a prominent role in phase 3 repolarization. LOF or GOF mutations in these channels disrupt normal cardiac repolarization and result in various cardiac rhythm disorders, including congenital LQTS, SQTS, and familial AFib ( Figures 1B and 4 (Continued ) July 6, 2018
and stable MDP, a ventricular-like AP morphology, and increased AP upstroke velocity comparable to that from freshly isolated human myocytes. 56, 57 Additional approaches including 3-dimensional tissue engineering, mechanical loading, modulation of substrate stiffness, phasic electrical stimulation, hormonal treatment (eg, thyroid hormone), and long-term culture have been used to enhance the maturity of hiPSC-CMs.
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Mechanisms of Arrhythmia
Although most hearts beat with remarkable fidelity and resilience, under certain circumstances, the rhythm of the heart can AFib indicates atrial fibrillation; AP, action potential; APD, action potential duration; AVN, atrioventricular node; BrS, Brugada syndrome; DPP6, dipeptidyl peptidase like 6; EAD, early afterdepolarization; EC, electromechanical coupling; GOF, gain-of-function; hiPSC-CM, human induced pluripotent stem cell-derived cardiomyocyte; hPSC, human pluripotent stem cells; KO, knockout; LOF, loss-of-function; LQTS, long-QT syndrome; LTCC, L-type Ca 2+ channel; MDP, maximum diastolic potential; MP, membrane potential; Ni, Nickel; RA, retinoic acid; RMP, resting membrane potential; SAN, sinoatrial node; and SQTS, short-QT syndrome.
*An array of accessory subunits is required in most cases to reconstitute a native current phenotype in a heterologous expression system. Many of these accessory subunits have not been completely characterized, have regional or species variability, 10 and in some cases led to conflicting results depending on the expression system used. It is not possible to provide an exhaustive list of all the accessory subunits for each channel here; only the important ones are listed.
†An exact comparison of current density (eg, for I Na and I to ) is difficult because of different experimental conditions (eg, temperature, different ionic concentrations, and holding potential), regional variability in expression in an intact heart (eg, epi-vs endocardium), and heterogeneous population of atrial-, ventricular-, and nodal-like hiPSC-CMs in cultures. fail. Accurate identification of specific mechanisms underlying arrhythmia may at times be challenging for the clinician and may require invasive electrophysiological study. Differentiating and understanding these complex mechanisms is critical to the development of appropriate diagnosis and treatment strategy. The fundamental mechanisms of arrhythmia can be classified into 2 major categories: (1) enhanced or abnormal impulse generation (focal activity), and (2) improper impulse conduction (reentry). Focal activity includes automaticity and triggered activity. 13, 66 Automaticity refers to the ability of cardiomyocytes to initiate spontaneous AP. Normally, the SAN has the highest intrinsic rate and sets the heart rate. Abnormal patterns of automaticity of the SAN can result in either sinus tachycardia or bradycardia. If the SAN is unable to generate impulses or if these impulses fail to propagate, latent pacemakers in other regions of the heart can take over initiating excitation. Atrial and ventricular myocytes, which in the normal heart typically do not exhibit spontaneous activity, may exhibit automaticity properties (eg, under β-adrenergic stimulation or reduced extracellular K + ). The spontaneity in SAN arises as a result of net inward current during the phase 4 of AP causing diastolic depolarization 67 ( Figure 2A ). Triggered activity arises from premature activation of cardiac tissues by 2 types of afterdepolarizations. 68 Early afterdepolarizations or EADs occur during phase 2 or 3 of AP repolarization, and delayed afterdepolarizations or DADs occur after repolarization is complete. When the amplitude of an afterdepolarization is large enough, a spontaneous AP can be triggered. 69 EADs are often but not always associated with prolonged APD which occur when the depolarizing currents (eg, I NaL , I CaL , or I NCX ) predominate the repolarizing currents (eg, I Kr , I Ks , and I K1 ). Two mechanisms have been proposed for EADs. First, the prolonged repolarization of the APD allows recovery and reactivation of I CaL , 70 resulting in enhanced inward I CaL that further depolarizes the membrane. This sets up a positive feedback loop, triggering a premature AP. 13 Second, at MPs negative to the threshold of I CaL activation (but before full repolarization), spontaneous Ca 2+ release from the SR can activate I NCX resulting in membrane depolarization 13 ( Figure 2B) Figure 2C ). When the depolarization induced by the DADs is sufficiently large, I Na can be activated resulting in triggered activity that also underlies arrhythmogenicity observed in catecholaminergic polymorphic ventricular tachycardia (CPVT). 13 Under normal conditions, the myocardium has a unidirectional propagation of depolarization wavefront that cancel each other out when the 2 meet from the opposite sides. Abnormal AP propagation can occur when a depolarization wavefront encounters a region that lags in recovery (ie, longer effective refractory period) from a previous depolarization, and thus the wavefront is blocked unidirectionally. However, the same region might be outside its effective refractory period when the wave reaches to the other end of this region (eg, Figure 2 . Key electrophysiological mechanisms of cardiac arrhythmia. Ectopic impulse generation by (A) enhanced automaticity. B, Action potential duration (APD) prolongation (in blue) leading to the development of phase 2 and phase 3 early afterdepolarizations (EADs; red). C, Development of delayed after depolarizations (DADs) that occur because of Ca 2+ overload. D, Reentry requires a vulnerable substrate, which can be caused by APD shortening or dispersion of refractoriness. Schematic shows a depolarizing wavefront around an anatomic obstacle. Under normal conditions, the depolarizing waves around the obstacle cancel each other out. Certain conditions, for example, ischemia might generate areas of unidirectional block or sufficiently slow conduction to enable recovery of excitability in time for re-excitation by the depolarizing wavefront. July 6, 2018 via propagating around the periphery of the region). This will lead to retrograde excitation of this region and the wavefront loops back and because of slow conduction might re-excite the adjacent regions that have recovered excitability. This circulating wave results in a circuitous and repetitive mode of depolarization, termed re-entry 71 ( Figure 2D ). The pathogenesis of arrhythmias in the whole heart is a complex phenomenon 72, 73 involving different layers of the myocardium, 3-dimensional cellular coupling, and different regions with unique structural and electrical features that can remodel with time. Although abnormal electrical behavior can be modeled in single cells, some events (eg, reentry) can be demonstrated only in multicellular preparations, such as monolayers of hiPSC-CMs. 74, 75 Caution must be exercised in extrapolating the findings from cellular studies to the whole heart.
Platforms for Functional Analysis of hiPSCCMs
iPSC technology has great potential to advance precision medicine. However, to be able to better use this human platform, appropriate methods for functional analysis of patient-specific iPSC-CMs are essential for understanding the pathogenic mechanisms of cardiac disorders, as well as performing preclinical safety studies for novel drug candidates. A concise overview of the commonly used methodology for iPSC-CM functional analysis is described below.
Patch Clamp
High fidelity intracellular electrical recordings from cardiomyocytes provide the most detailed and precise evaluation of the electrophysiological properties of cardiomyocytes. Sharp electrodes penetrating the cell membrane can accurately record MP and thus characterize APs in detail. The patch clamp technique 76 provides the opportunity to measure both MP (or AP) and underlying ionic currents. The technique involves gently pressing a fine-tip glass pipette, containing a solution with an ionic composition similar to the cytosol, against the cell membrane using a precision micromanipulator under guidance from an inverted microscope, followed by application of a mild suction to obtain a high resistance seal between the glass pipette and the cell membrane. Once a giga-ohm resistance seal is formed, the small patch of membrane plugging the pipette tip can be ruptured to provide electrical access to the inside of the cell, a recording configuration known as the whole-cell patch clamp technique ( Figure 3A ) that allows the measurement of APs in current-clamp mode or membrane currents in voltage-clamp mode.
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Many seminal studies of channelopathies have used the patch clamp method for electrophysiological analysis of hiP-SC-CMs. 40, 43, 82, 83 The biggest disadvantage of the patch clamp method remains its low throughput. The recordings are laborious, technically challenging, and requires skilled personnel. Moreover, the invasive and terminal nature of the technique allows recordings to be performed only for a short period of time from single cells. However, it provides high time (<1 ms) and voltage-or current-amplitude resolution (unmatched by any other technique) while allowing control of the intracellular and extracellular ion composition. 7, 76 Furthermore, using specific blockers and recording protocols that can control the MP, activity of an individual ion channel (or whole-cell current) can be separated from other ion currents with high fidelity.
Multielectrode Array
Multielectrode array (MEA) is a noninvasive and nonterminal method that allows long-term measurements of extracellular field potential signals from clusters and monolayers of hiPSCCMs. 84 CMs are plated on the wells of the MEA plate containing electrodes on the bottom, and field potential is measured. The field potential duration correlates roughly to the QT interval in the in vivo ECG and the APD in vitro. The field potential signal is composed of an initial rapid spike that corresponds to the AP upstroke, a slow wave/plateau phase, followed by a repolarizing wave that corresponds to repolarization 77, 85, 86 ( Figure 3B ). During the past few years, MEAs have been increasingly used for predicting cardiotoxicity (manifested as prolonged field potential durations and development of triggered activity) of hiPSC-CMs and can be scaled up for moderate throughput. The MEA platform is widely accepted and a relatively easy to understand assay. 78, 87, 88 MEA allows generation of detailed activation maps and conduction velocity measurements; however, the conduction velocity in hiPSC-CMs monolayers is relatively slow (10-20 cm/s compared with 60 cm/s in adult human left ventricle) likely because of the immaturity of hiPSC-CMs. 89 The disadvantages of the MEA method are its low resolution and inability to analyze ionic currents.
Fluorescence Imaging
Fluorescence microscopy methods that use Ca 2+ -or voltagesensitive dyes provide a noninvasive method for measuring intracellular ion fluctuations and voltage changes. However, such indicator dyes can bind to intracellular molecules likely interfering with the normal functioning of the cell, and most Ca 2+ indicator dyes, including Fura-2 and Fluo-4, are cytotoxic. Despite novel developments in software tools used for data analysis, Ca 2+ imaging remains a rather slow method, both for performing the assay itself and for data analysis. 90 Voltage-sensitive dyes, such as di-4-ANEPPS, respond to changes in MP by changing their fluorescence emission. They are commonly used for studying whole hearts but have their limitations in single cell and monolayer imaging because of significant cytotoxicity. 91 To overcome these challenges, genetically encoded fluorescent indicators (genetically encoded calcium indicator for intracellular calcium ions and genetically encoded voltage indicator for voltage) were recently introduced to improve the efficiency of cellular phenotyping in hiPSC-CMs. These genetically encoded indicators consist of a sensing element (eg, calmodulin for Ca 2+ ), often fused to an autofluorescent protein (like circularly permuted enhanced green fluorescent protein ) that alters its fluorescent intensity based on conformational changes in the sensing element 80 ( Figure 3C ).
In a recent study, Shinnawi et al 80 demonstrated successful expression of genetically encoded voltage (ArcLight) and calcium (GCaMP5G) fluorescent indicators in hiPSC-CMs derived from patients with different IAS. 80 The use of these reporters in comparison to traditional voltage-and Ca 2+ -sensitive dyes offers several advantages, including significant photostability, superior signal-to-noise ratio, and minimal cytotoxicity. Most fluorescent dyes (except Fura-2, which is ratiometric) and all genetic indicators allow monitoring of only relative changes in membrane voltage and intracellular Ca 2+ levels and do not provide absolute values. 80 
Impedance
Functional assays based on cellular impedance (an indirect measure of cardiomyocyte contractility) offer a noninvasive, label-free, and high throughput analysis method. 92 Cells are seeded onto a multiwell cell culture plate that contains gold film electrodes embedded onto the bottom of the wells. The mechanical displacement of the cells during cardiomyocyte contraction is measured as variations in impedance (equivalent to resistance in a direct current circuit) that directly correlates with the beating frequency ( Figure 3D ). These measurements use weak alternating current between the electrodes with tissue culture medium as the electrolyte. The electronic hardware monitors the voltage across the electrodes, and the impedance is calculated using the alternating current version of Ohm law where impedance (Z) rather than resistance (R) is calculated as Z=V/I. Monitoring of the impedance signal does not alter cellular physiology either in an excitatory, suppressive, or cytotoxic fashion. 92 Clearly, this method has great potential in ascertaining the beat rate/arrhythmogenicity of hiPSC-CMs, however caution should be taken to avoid overinterpreting the data. It is important to realize here that the changes in the beating pattern of the cells are recognized only because of a measurement of a minute change in resistance and not because of their direct electrical activity. 93 Impedance measurements have been validated for mouse embryonic stem cells, 94 hiPSC-CMs, 94 rat neonatal primary CMs, 95, 96 and further cell lines, for example, cardiac muscle cells (HL-1) and 3-dimensional cell clusters (human embryonic stem cellderived cardiomyocytes). 94 The recently introduced Cardio ECR platform (ACEA Biosciences) combines MEA with contractility measurements for a simultaneous and more comprehensive analysis of the excitation-contraction coupling.
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IAS and hiPSC Modeling
Molecular and biophysical studies during the past 2 decades have linked genetic mutations in ion channels or ion channel regulatory proteins (genotype) to IAS (phenotype). These disorders include long-QT syndrome (LQTS), short-QT syndrome (SQTS), Brugada syndrome (BrS), CPVT, and familial atrial fibrillation (AFib).
67 Table 2 summarizes the genotypephenotype correlation of various channelopathies. As illustrated in Figure 4, ; CALM1, calmodulin 1; CALM2, calmodulin 2; CPVT, catecholaminergic polymorphic ventricular tachycardia; DAD, delayed after depolarization; EAD, early after depolarization; hERG, human ether-a-go-go related gene; hiPSC, human induced pluripotent stem cell; LQTS, long-QT syndrome; LTCC, L-type Ca 2+ channel; MEA, multielectrode array; PKP2, plakophilin-2; and SR, sarcoplasmic reticulum. Although several genetic mutations have been associated with BrS, all lead to a general imbalance of currents during the early phases of the AP tipping in favor of repolarization. The most common and best studied of these is the loss-of-function (LOF) mutation of the SCN5A gene (encoding Na v 1.5) 71 leading to reduced Na + channel availability, either through decreased surface channel expression or through altered channel gating properties. 119, 120 Although much of our current understanding on the molecular mechanisms of BrS was gleamed from heterologous expression studies, recently, patient-specific iPSC-CMs harboring LOF genetic mutations in SCN5A were shown to recapitulate the proarrhythmic phenotype associated with either BrS 109, 121 or overlapped LQT3/BrS.
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Long-QT Syndrome
LQTS is a potentially lethal cardiac disorder, characterized by QT interval prolongation and increased risk of ventricular arrhythmias, particularly torsade de pointes that can lead to sudden cardiac death. Increased arrhythmic risk associated with a prolonged QT interval can be congenital or acquired. Congenital LQTS is associated with mutations in ion channels and accessory proteins, whereas acquired QT prolongation is most commonly associated with block of the human ether-a-go-go related gene K + channel by some antiarrhythmic agents or as an unwanted side effect of many other medications. In addition, it can be associated with electrolyte imbalance (hypokalemia, hypocalcaemia, and hypomagnesaemia). The mutations associated with LQTS result in a favoring of depolarizing currents over repolarizing ones during phases 2 and 3 of the AP. 71 At the single-cell level, LQTS results from prolongation of the APD that can initiate EADs and torsade de pointes arrhythmia that sometimes degenerates into potentially lethal ventricular fibrillation.
Long-QT Syndrome Type 1
LQTS1 is the most common type of LQT disorders that accounts for ≈40% of total cases, often triggered by adrenergic drives, for example, emotional stress, physical exertion, diving and swimming, etc. LQTS1 results from LOF mutations in the KCNQ1 gene that encodes the α-subunit of the channel conducting I Ks . LQTS1 patients respond well to β-blockers while some are less responsive or even resistant to this medication. 123 Moretti et al 43 were the first to model LQTS1 using hiPSCCMs derived from a patient carrying the R190Q KCNQ1 mutation. This missense mutation caused a trafficking defect that reduced KCNQ1 protein surface expression, leading to a 70% reduction in I Ks . Consequently, the diseased cells recapitulated the hallmark LQTS phenotype characterized as APD prolongation and an increase in arrhythmia with β-adrenergic agonists. Propranolol pretreatment reduced isoproterenol-induced arrhythmias in spontaneously beating LQTS1 hiPSC-CMs. 43 In a later study, Ma et al 99 derived iPSC-CMs from a LQTS1 patient harboring a different KCNQ1 mutation (exon 7 del) and demonstrated that patient-specific iPSC-CMs faithfully recapitulated the clinical phenotype and responded to a small molecule ML277, an investigational agent under development to treat arrhythmia. Egashira et al 124 generated iPSC-CMs from a sporadic LQTS patient with 1893delC mutation in the KCNQ1 gene with clinical suspicion of LQTS1. MEA recordings revealed markedly prolonged field potential duration, a characteristic of LQTS phenotype. Further analysis identified a trafficking defect in KCNQ1 as the cause of the patient's clinical phenotype. Taken together, these findings clearly demonstrate the potential of patient-specific hiPSC-CMs as robust models for IAS despite their relatively immature electrophysiological profile.
Long-QT Syndrome Type 2
LQTS2 accounts for 30% of all LQTS cases and is caused by LOF mutations in the KCNH2 (human ether-a-go-go related gene 1) gene that encodes the α-subunit of the channels that conduct I Kr . An auditory stimulus is often a trigger for arrhythmic events in LQTS2 patients. The first reports of iPSC-based models of LQTS2 were reported by Itzhaki et al 41 and Matsa et al. 125 It was demonstrated 41 that hiPSC-CMs derived from a patient with missense mutation A614V in KCNH2 exhibited significant prolongation of the AP, smaller I Kr , EADs, and triggered arrhythmias. Importantly, the authors evaluated the potency of several pharmacological agents that worsened or mitigated the cellular LQTS2 phenotype. In a later study, 125 hiPSC-CMs were derived from a patient with the A561T mutation in KCNH2. The authors 125 used allele-specific RNA interference to selectively degrade mutant mRNA while leaving wild-type mRNA intact. This approach normalized the APD, increased I Kr , and decreased the frequency of EADs. In a recent study, Mehta et al 126 provide solid evidence in favor of hiPSCs having promising drug repurposing applications with regard to the development of precision medicine treatment of LQTS. The authors demonstrated that Lumacaftor, a drug already in clinical use for cystic fibrosis because of its ability to foster trafficking of mutant cystic fibrosis transmembrane conductance regulator channels to the cell surface, can also rescue the pathological phenotype of class 2 (trafficking deficient) LQTS2 hiPSC-CMs derived from patients not protected by β-blockers.
Long-QT Syndrome Type 3
LQTS3 is caused by gain-of-function mutations in the SCN5A (Nav1.5) gene that accounts for ≈10% of all LQTS cases. Most of these mutations result in enhanced late Na + current (I NaL ) during the plateau and repolarization phase of the AP because of defective inactivation of the Nav1.5 channel. The net increase in the depolarizing current ultimately causes APD prolongation and proarrhythmia. In contrast to the triggers of LQTS1 and LQTS2, which are often increased heart rate and stressful auditory stimuli, respectively, LQTS3 patients exhibit QT prolongation at lower heart rates and, consequently, have an increased risk for cardiac events during rest or sleep.
127 LQTS3 models of patient-specific hiPSC-CMs have been shown to recapitulate key electrophysiological disease features, such as increased I NaL and prolonged APD at the single-cell level. 78, 103 Ma et al 101 modeled LQTS3 in hiPSC-CMs derived from a patient with the V1763M mutation in SCN5A and demonstrated enhanced I NaL and prolonged APD. Interestingly, mexiletine, a Na + channel blocker, preferentially inhibited I NaL and rescued the abnormal electrophysiology in diseased cells.
In an elegant study, Terrenoire et al 102 investigated the underlying cause of pathogenicity in a patient with variants in both SCN5A (F1473C) and KCNH2 (K897T). The authors demonstrated by patch clamp recordings that the observed clinical phenotype of severe QT prolongation and arrhythmias was primarily because of late Na + channel defect and not influenced by the KCNH2 polymorphism. Interestingly, specific to the patient's hiPSC-CMs, I NaL displayed pronounced ratedependence such that enhancing the pacing rate markedly reduced I NaL and increased its inhibition by mexiletine. This type of analysis clearly demonstrates the promise of patient-specific hiPSC-CM platform in improving management of IAS and for developing patient-specific clinical regimens.
Long-QT Syndrome Type 7
LQTS7, also known as Andersen-Tawil syndrome (ATS), is a rare autosomal dominant genetic disorder typified by mild QT interval prolongation and appearance of significant U waves, frequent ventricular ectopy, bidirectional ventricular tachycardia, and more rarely syncope, recurrent polymorphic ventricular tachycardia, and cardiac arrest. Exercise is an important trigger of ventricular tachyarrhythmia and syncope in some patients with ATS, therefore patients are commonly treated with β-blockers. ATS type-1 has been linked to mutations in KCNJ2 128 and accounts for ≈70% of all ATS cases. The genetic cause of the remaining 30% of cases (ATS type 2) remains unknown.
129 KCNJ2 encodes for the Kir2.1 potassium channel that contributes to I K1 . Most KCNJ2 mutations in ATS type-1 cause LOF and dominant-negative suppression of Kir2.1 channel function, leading to reduced I K1 . 130, 131 Recently Kuroda et al 105 modeled ATS using the hiPSC platform. A significant challenge in modeling LQTS7 is that because I K1 density is already compromised in hiPSC-CMs, it is difficult to obtain a clear difference between healthy control and diseased hiPSC-CMs using voltage clamp techniques. But interestingly, in this study, the authors used MEA and Ca 2+ imaging platforms to uncover the pathogenesis of ATS in patient-derived hiPSC-CMs. hiPSC-CMs from 3 ATS patients carrying either one of the KCNJ2 mutations (R218W, R218Q, or R67W) clearly exhibited arrhythmic events and abnormal Ca 2+ release that was significantly suppressed by flecainide and a reverse-mode Na + /Ca 2+ exchanger (NCX) inhibitor.
More recently, a new role of hiPSC-CMs has emerged in deciphering the pathogenicity of variants of uncertain significance. Recent advances in sequencing technologies have made it feasible to sequence the entire exome of patients suspected of having LQTS to identify causal genes. Such testing can identify hundreds of novel nonsynonymous coding variants in any given individual 132 and determining which one of them is pathogenic or benign is currently the biggest challenge in the management of IAS, especially when the variant is of uncertain significance. Using the iPSC platform, Gelinas et al 133 demonstrated the pathogenicity of a novel variant Gly52Val in the KCNJ2 gene identified by whole-exome sequencing in an LQTS8 patient. Patient-specific hiPSC-CMs displayed significant APD prolongation and incidence of arrhythmia.
Immunohistochemistry and whole-cell current recordings in human embryonic kidney cells heterologously expressing the wild-type or the mutant Kir2.1 channel further confirmed a surface trafficking defect in the mutant channels.
In future studies, the creation of isogenic hiPSC lines with single variant changes using CRISPR (clustered regularly interspaced short palindromic repeats) genome editing will allow direct comparison of phenotypes at a cellular level. A unique advantage of genome editing technology in disease modeling is the ability to study variants in an isogenic background to rule out phenotypic variability from epigenetic differences or unknown genetic modifiers. 134 This novel approach of combining iPSCs and genome editing technology to decipher variants of uncertain significance pathogenicity in LQTS could aid in tailoring drug treatment and implantable cardioverter defibrillator therapy and could potentially be applied to other cardiac disorders to accelerate progress toward realizing the promise of precision medicine in IAS.
We recently validated this approach in our laboratory 135 by generating hiPSC-CMs from a variant of uncertain significance carrier of LQTS2 (T983I KCNH2) and demonstrated their aberrant electrophysiological phenotype (reduced I Kr and prolonged APD). We further delineated the variants of uncertain significance pathogenicity using CRISPR genome editing to selectively correct the variant which normalized the abnormality and introduced the homozygous KCNH2 variant in an otherwise healthy individual which exacerbated the disease phenotype. To our knowledge, this is the first report of combining human iPSC and genome editing platforms to decipher pathogenicity of uncertain variant.
Long-QT Syndrome Type 8
LQTS8 (Timothy syndrome) results from rare single amino acid substitutions in CACNA1C gene that encodes the LTCC. It is the most severe form of LQTS, characterized by multiorgan dysfunction and high mortality. Besides marked QT interval prolongation and severe ventricular arrhythmia, LQTS8 patients can present with congenital heart defects, atrioventricular block, syndactyly, autism, malignant hypoglycemia, and an abnormal immune system. 136, 137 The G406R and G402S mutations in CACNA1C reduce the rate of channel inactivation and thereby prolong the plateau phase of the cardiac AP. 136, 137 In 2011, Yazawa and Dolmetsch 83 modeled LQTS8 using patient-specific hiPSC-CMs. The diseased cells recapitulated electrical abnormalities, such as prolonged APD, DADs, and altered Ca 2+ transients. Roscovitine accelerated I CaL inactivation, reduced APD, restored the irregular Ca 2+ transient, and decreased the frequency of abnormal depolarizations in LQTS8 hiPSC-CMs. 83 Although roscovitine rescued the electrophysiological abnormality in LQTS8 hiPSC-CMs, the exact mechanism by which it restored cardiac function was not clear. In a separate study, 138 it was shown that roscovitine exhibits its therapeutic effects, in part, by inhibiting CDK5, a key mediator involved in the regulation of Ca V 1.2 channels in CMs. These studies provide mechanistic insights into the regulation of Ca V 1.2 and the development of future therapeutics for Timothy syndrome patients.
Catecholaminergic Polymorphic Ventricular Tachycardia
CPVT is an inherited disease characterized by abnormal intracellular Ca 2+ handling and signaling in CMs. The underlying mechanism of CPVT involves abnormal Ca 2+ release from the SR, which is often due either to gain-of-function mutations in RYR2 (CPVT1) 139 or LOF mutations in calsequestrin (CPVT2), an SR calcium buffering protein. Such abnormal Ca 2+ release may cause DADs, similar to digitalis toxicity, leading to triggered activity and ventricular tachyarrhythmias. Clinically, CPVT is precipitated by increased levels of catecholamines (eg, epinephrine) under conditions of emotional stress and physical exertion. β-Blockers are the drugs of choice for CPVT patients, but they often fail to prevent fatal arrhythmias.
To date, several groups have successfully modeled CPVT using the hiPSC platform.
111-113 CPVT1 patient-specific hiP-SC-CMs carrying the F2483I mutation in the RYR2 112 recapitulated DADs after catecholaminergic stimulation while Ca 2+ imaging studies revealed higher amplitudes and longer durations of spontaneous Ca 2+ release at basal state compared with control hiPSC-CMs. In addition, the calcium-induced calcium release events continued after repolarization that were abolished by forskolin. In yet another CPVT1 model of hiPSCCMs harboring the RYR2-M4109R mutation, 111 hiPSC-CMs showed increased DAD incidence and Ca 2+ transient irregularities as compared with control hiPSC-CMs, which were further exacerbated by β-adrenergic stimulation. 111 Flecainide eliminated DADs in this CPVT1 hiPSC-CM model. 111 These data indicate that hiPSC-CMs can recapitulate the cardinal features of CPVT, making them useful models to investigate IAS mechanisms and to expedite personalized therapy.
Short-QT Syndrome
SQTS is a rare inheritable, autosomal dominant disorder characterized by accelerated cardiac repolarization, abnormally short QT intervals, and an increased propensity to develop atrial and ventricular tachyarrhythmia. Cardiac arrest seems to be the most frequent symptom (up to 40%). 140 SQTS has been associated with mutations in 6 genes (KCNQ1, KCNH2, KCNJ2, CACNA1C, CACNB2, and CACNA2D1) with gain-of-function mutations in KCNH2 (SQTS1) being the most prevalent subtype. 141, 142 Because it is a repolarization abnormality, the causative ion channel genes overlap with those of BrS and LQTS (Figure 4 ). In addition, AFib or atrial flutter is also observed in SQTS patients (particularly SQT1). 143 Besides implantable cardioverter defibrillator, several pharmacological approaches have been applied to treat SQTS, all aiming to restore the duration of ventricular repolarization to physiological values. Gaita et al 144 tested several antiarrhythmic drugs (flecainide, sotalol, ibutilide, and hydroquinidine) on 2 SQTS families carrying the N588K mutation in KCNH2. 144 Hydroquinidine was found to be the only agent that effectively prolonged the QT interval and abolished the inducibility of ventricular arrhythmias during programmed electrical stimulation.
To date, there has been only one report of modeling SQTS using the hiPSC platform. El-Battrawy et al 145 demonstrated that hiPSC-CMs derived from a patient carrying a N588K mutation in the KCNH2 recapitulated single-cell phenotype of SQTS. In contrast to the single-cell phenotype of LQTS2, SQTS patient-specific hiPSC-CMs displayed markedly enhanced I Kr density and shortened APD compared with healthy control. These cells further demonstrated abnormal Ca 2+ transients and arrhythmic activities. Carbachol increased the arrhythmic events in SQTS while quinidine, but not sotalol or metoprolol, prolonged the APD and abolished arrhythmic activity induced by carbachol. These studies provide novel opportunities to further elucidate the pathophysiological mechanisms of SQTS and development of effective treatment strategies.
Atrial Fibrillation
AFib represents the most common type of supraventricular arrhythmia especially in the elderly population, oftentimes associated with underlying ischemic or structural heart disease, hypertension, diabetes mellitus, autonomic imbalance, as well as electrical remodeling of the atria. An underlying genetic component ( Figure 4 ) has been associated with AFib only in a small number of cases of lone AFib (AFib in the absence of predisposing factors); however, inheritance is complex and mostly non-Mendelian. 146 The primary arrhythmia mechanisms contributing to AFib are focal ectopic firing and reentrant activity ( Figure 2D ). Ablation techniques have improved outcomes during the past 2 decades but are associated with a risk of complications and are only successful in a limited number of patients with permanent AFib. Pharmacological therapy remains as the first-line treatment, and an important adjuvant to ablation therapy, however it is limited by a lack of efficacy and serious side effects, such as ventricular proarrhythmia.
One of the major barriers to an improved mechanistic understanding of AFib, and thus drug development, has been a lack of appropriate models. 74 Until recently, hiPSC-based models of AFib were lacking because most hiPSC-CM differentiation protocols tend to generate a predominant ventricular-like phenotype. This methodological hurdle has been recently solved by manipulation of retinoic acid signaling, a physiological pathway that also drives atrial specification in vivo. 36, 147 Recently, Laksman et al 74 used human embryonic stem cell to generate an atrial-specific tissue model of AFib for pharmacological testing. These atrial-like cardiomyocyte sheets showed uniform AP propagation, and rapid reentrant rotor patterns as seen in AFib could be induced. It was demonstrated 74 that antiarrhythmic drugs such as flecainide and dofetilide modulated reentrant arrhythmogenic rotor activation patterns in a manner that helps explain their efficacy in treating and preventing AFib.
Limitations of hiPSC-CMs
hiPSC-CMs have emerged as a promising experimental tool for translational cardiovascular research and drug development. However, their applicability as a human adult cardiomyocyte model is still hindered by several limitations. We have already mentioned on several occasions in this review, one of the major limitations of hiPSC technology-the immaturity of hiPSC-CMs. Compared with adult CMs, immature hiPSC-CMs have several differences, including a lack of T-tubules, abnormal morphology, altered gene expression, and reduced sarcomere organization. 148, 149 Genetic modifications during reprogramming, incomplete reprogramming resulting in residual epigenetic memory, induced alterations during passaging in culture, and differentiation-dependent variability and heterogeneity of iPSC-CMs are additional problems. 150 With regard to the challenges specific to disease modeling, it is not yet possible to model all human diseases using the hiPSC platform, for example, diseases based on complex interactions of multiple genetic and environmental factors or on long incubation time, such as atherosclerosis and congenital heart diseases. 151 Moreover, differences in the individual genetic background present a particularly vexing problem to the disease-in-a-dish approach because of the uncontrolled impact of genetic modifier loci. Thanks to the recent advances in genome editing tools, such as zinc finger nucleases, transcription activator-like effector nuclease, and CRISPR genome editing, this limitation can now be addressed using genetically manipulated isogenic controls. 150 The robust combination of hiPSCs and genome editing will provide a unique opportunity to systematically and faithfully recapitulate human diseases in vitro, revealing new insights into the pathophysiology of monogenic and complex disorders. 150 However, to use hiPSCs for precision medicine, the development of improved differentiation protocols and 3-dimensional bioengineering approaches to create mature, adult-like CMs will be of paramount importance.
Conclusions and Future Perspectives
IAS represents a group of potentially lethal disorders that remain a diagnostic and therapeutic challenge because of complexity of the disorder and variable disease penetrance. Studies based on in vitro expression of mutations and transgenic animal models have been instrumental in offering the practitioner tools for deciphering these rare disorders, but their potential remains limited. At present, there are still many unanswered questions, such as why mutations in the same gene can cause different types of arrhythmias or why patients carrying the same mutation may exhibit completely different phenotypes ranging from being completely asymptomatic throughout life to experiencing sudden cardiac death at an early age. In this regard, the role of the genetic modifiers that modulate the outcome in a mutation-and patientspecific manner remains unknown. Recent advances in the derivation of hiPSCs directly from diseased patients now provide a great opportunity to unravel these diverse mechanisms unique to a mutation/patient. Combined with the rapidly advancing genome editing approaches, iPSC technology has already emerged as a powerful platform for studying genotype-phenotype association and for predicting patient response to individualized therapy. 71 Cleary, iPSCs hold enormous potential in advancing the practice of precision medicine. In the future, a more thorough knowledge of the disease processes of these syndromes may enable us to use targeted therapy alone and minimize the need for implantable cardioverter defibrillators.
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